AI Health’s Billion Dollar VBC Readiness Gap

The promise of artificial intelligence in healthcare is vast, yet its integration into value-based care (VBC) models remains surprisingly limited for many platforms. While AI health solutions frequently tout innovation and efficiency, a critical gap exists between these claims and the rigorous evidence required for VBC contracts. This disparity creates a significant challenge for investors and health plan executives alike, forcing a reevaluation of what truly constitutes “readiness” in the evolving landscape of healthcare reimbursement.

The VBC Imperative: Outcomes Over Optimism

Value-based care models, championed by organizations like CMS and CMMI, fundamentally shift the focus from fee-for-service volume to measurable patient outcomes and cost reduction. For AI health platforms to participate meaningfully in these arrangements, they must demonstrate clear, auditable financial performance and clinical efficacy. This isn’t merely about having a clever algorithm; it’s about proving that the algorithm delivers tangible, peer-reviewed results that align with payer incentives. The stark reality is that, as of today, 80%+ of AI health platforms lack the peer-reviewed evidence, auditable ROI, or performance guarantees needed for VBC (CW6-DP-15). This “VBC Readiness Gap” represents a significant hurdle for many promising technologies. Consider the diverse landscape of AI health companies. Platforms like Omada Health and Hinge Health focus on chronic disease management and musculoskeletal conditions, respectively. Spring Health addresses mental health, while iRhythm Technologies provides AI-powered cardiac monitoring. Then there are consumer-facing apps such as Noom for weight management, BetterHelp for therapy, and wellness tools like Calm, Headspace, and Oura. Even infrastructure players like Commure aim to streamline healthcare operations. Each of these, to varying degrees, leverages AI to enhance their offerings. However, the critical distinction for VBC eligibility lies not just in their AI capabilities, but in their ability to robustly quantify the value they generate. Hemant Taneja, a prominent investor in health tech, has frequently emphasized the need for healthcare innovations to demonstrate clear value to payers. Similarly, Eric Topol, a leading voice in digital medicine, consistently advocates for rigorous clinical validation of AI tools before widespread adoption. Their insights underscore a fundamental truth: without verifiable outcomes data, AI health platforms struggle to move beyond pilot programs and secure long-term, scalable VBC contracts. The onus is on these companies to invest in the research and data collection necessary to prove their worth in a VBC framework.

Unpacking the Evidence Deficit: Why Most AI Health Platforms Fall Short

The inability of a majority of AI health platforms to qualify for value-based contracts stems from several key areas of evidence deficit. First and foremost is the lack of peer-reviewed clinical outcomes data. Many platforms can point to internal studies or anecdotal success stories, but these rarely meet the stringent requirements of health plans or VBC organizations. Payers, guided by organizations like AHIP and NCQA, demand evidence that stands up to scientific scrutiny, demonstrating improved patient health, reduced hospitalizations, or decreased overall healthcare costs. For example, while platforms like Noom, BetterHelp, Calm, and Headspace offer valuable services leveraging AI for personalized experiences, the depth and breadth of their peer-reviewed evidence demonstrating direct, attributable cost savings or significant long-term clinical improvements often fall short of VBC requirements. Similarly, even innovative hardware like Oura, which collects vast amounts of physiological data, needs to translate that data into proven interventions that reduce downstream medical costs or prevent adverse events, a challenge that requires significant clinical research. Even for platforms with more established clinical applications, like iRhythm Technologies, the journey to VBC integration requires continuous evidence generation and transparent reporting. The complexity of healthcare data, coupled with the need to isolate the specific impact of an AI intervention from other care components, presents a formidable research challenge. This is where the 80%+ figure becomes particularly salient; many AI health companies are still in the early stages of building the robust evidence base that VBC demands. They may possess compelling technology, but without the “receipts” of validated outcomes and financial performance, their path to VBC contracts remains obstructed.

Regulatory and Payer Expectations: The Unyielding Standards of VBC

The regulatory landscape, shaped by entities such as CMS and NCQA, sets clear expectations for VBC participation. CMS VBC Rules, for instance, are designed to incentivize providers and technology partners to deliver high-quality, cost-effective care, with a strong emphasis in 2026 on two-sided financial risk and clinician-level accountability. This means that any AI health platform seeking to integrate into these models must demonstrate not only clinical efficacy but also adherence to data privacy, security, and interoperability standards. NCQA Standards further reinforce the need for quality measurement and continuous improvement, pushing platforms to collect and report on a defined set of performance metrics, including new Digital Health Engagement Accreditation programs in 2026. The regulatory environment for healthcare AI is rapidly evolving and fragmenting, with many states introducing and passing new laws focused on transparency, licensed oversight, and scrutiny for AI in clinical and patient-facing contexts. Health plan executives, often advised by organizations like Rock Health and ACC, are increasingly sophisticated in their evaluation of digital health tools. They are not merely looking for innovative technology; they are seeking partners who can demonstrate a clear return on investment through reduced medical spend, improved member engagement, and better health outcomes. This requires robust data analytics capabilities, transparent reporting, and often, performance-based contracting models where payment is tied directly to achieving predetermined outcomes. Payer requirements for VBC contracts with digital health vendors Digital health funding in Q1 2026 saw $4 billion in venture capital, concentrated in megadeals for AI-enabled startups, indicating a selective market that prioritizes proven value. The current environment demands that AI health platforms move beyond simply showcasing their technological prowess. They must actively engage in generating real-world evidence (RWE), conducting rigorous studies, and publishing their findings in peer-reviewed journals. This commitment to evidence generation is not merely a good practice; it is a prerequisite for entry into the lucrative and expanding realm of value-based care. Without it, even the most innovative AI solutions risk being sidelined, unable to fully capitalize on the shift towards outcomes-driven healthcare.

The Path Forward: From Innovation to Irrefutable Value

The “AI Health VBC Readiness Gap” highlights a critical inflection point for the industry. For investors, this gap signals a need for deeper due diligence into the evidence base of potential portfolio companies. Investing in platforms that have proactively built a foundation of peer-reviewed outcomes data, auditable ROI, and a willingness to engage in performance guarantees will be key to unlocking long-term value. For health plan executives, this gap underscores the importance of demanding rigorous evidence from all AI health vendors, ensuring that adopted solutions genuinely contribute to cost reduction and improved patient health. Guide for health plans evaluating AI health solutions The future of AI in healthcare is undoubtedly bright, but its integration into value-based care models will be dictated by demonstrable, quantifiable impact. The critical advancement in VBC AI in 2026 includes an “action layer” where AI agents can autonomously execute tasks, moving beyond just analytics to directly impact outcomes. The current landscape, where 80%+ of AI health platforms struggle to meet VBC requirements, presents both a challenge and an immense opportunity. Those companies that prioritize rigorous evidence generation, embrace transparency, and align their incentives with value-based care principles will be the ones that ultimately thrive, transforming healthcare delivery one outcomes-driven contract at a time. Rock Health report on digital health funding and evidence